DTIL vs. TIL, ATRA, ELUT, TSBX, CGTX, IKNA, JATT, ATHA, PLX, and GNTA
Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Instil Bio (TIL), Atara Biotherapeutics (ATRA), Elutia (ELUT), Turnstone Biologics (TSBX), Cognition Therapeutics (CGTX), Ikena Oncology (IKNA), JATT Acquisition (JATT), Athira Pharma (ATHA), Protalix BioTherapeutics (PLX), and Genenta Science (GNTA). These companies are all part of the "biological products, except diagnostic" industry.
Instil Bio (NASDAQ:TIL) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Instil Bio has a net margin of 0.00% compared to Instil Bio's net margin of -125.84%. Precision BioSciences' return on equity of -51.27% beat Instil Bio's return on equity.
Instil Bio received 7 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 66.92% of users gave Precision BioSciences an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.
Instil Bio currently has a consensus price target of $25.00, indicating a potential upside of 110.44%. Precision BioSciences has a consensus price target of $46.33, indicating a potential upside of 298.74%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Instil Bio.
Precision BioSciences has higher revenue and earnings than Instil Bio. Precision BioSciences is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Precision BioSciences had 3 more articles in the media than Instil Bio. MarketBeat recorded 10 mentions for Precision BioSciences and 7 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.79 beat Precision BioSciences' score of -0.24 indicating that Precision BioSciences is being referred to more favorably in the news media.
Instil Bio has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
60.6% of Instil Bio shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 54.7% of Instil Bio shares are held by insiders. Comparatively, 5.1% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Precision BioSciences beats Instil Bio on 11 of the 17 factors compared between the two stocks.
Get Precision BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precision BioSciences Competitors List
Related Companies and Tools
